Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 3/2011

01-06-2011 | Clinical Trial Report

Systemic Inflammation and the Dynamics of HDL Cholesterol–Associated Residual Cardiovascular Risk

Author: Robert S. Rosenson

Published in: Current Atherosclerosis Reports | Issue 3/2011

Login to get access

Excerpt

Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard et al., for the JUPITER Trial Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010;376:333–9. …
Literature
1.
Fruchart JC, Sacks F, Hermans MP, et al. Executive statement, the residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidemic patients. Diab Vasc Dis Res. 2008;5:319–35.PubMedCrossRef
2.
Barter P, Gotto AM, LaRosa JC, et al. HDL-cholesterol, very low levels of LDL-cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10.PubMedCrossRef
3.
Rosenson RS. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Am Heart J. 2006;151:556–63.PubMedCrossRef
4.
West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440–5.
5.
Ridker PM, Gesest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376:333–9.PubMedCrossRef
6.
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRef
7.
Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL-cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE-IT TIMI 22. Arterioscler Thromb Vasc Biol. 2009;29:424–30.PubMedCrossRef
8.
Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol. 2003;92:1447–51.PubMedCrossRef
9.
Rosenson RS, Davidson MH, Pourfazib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic risk. Atherosclerosis. 2010;213:1–7.PubMedCrossRef
10.
Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on low-density and high-density lipoprotein particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care. 2009;32:1087–91.PubMedCrossRef
11.
Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477–84.PubMed
12.
Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113:1556–63.PubMedCrossRef
13.
Vaiser T, Pennathur S, Greene PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest. 2007;117:595–8.CrossRef
14.
Rosenson RS. Functional assessment of HDL: Moving beyond static measures for risk assessment. Cardiovas Drugs Ther. 2010;24:71–5.CrossRef
Metadata
Title
Systemic Inflammation and the Dynamics of HDL Cholesterol–Associated Residual Cardiovascular Risk
Author
Robert S. Rosenson
Publication date
01-06-2011
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 3/2011
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-011-0167-2

Other articles of this Issue 3/2011

Current Atherosclerosis Reports 3/2011 Go to the issue

ReviewPaper

Role of Hepatic Lipase and Endothelial Lipase in High-Density Lipoprotein—Mediated Reverse Cholesterol Transport

ReviewPaper

Experimental Models for the Investigation of High-Density Lipoprotein–Mediated Cholesterol Efflux

ReviewPaper

Lecithin Cholesterol Acyltransferase: An Anti- or Pro-atherogenic Factor?

ReviewPaper

Genome-Wide Association Studies in Atherosclerosis

ReviewPaper

MicroRNAs in Cardiometabolic Disease

ReviewPaper

Genetic Mechanisms Mediating Atherosclerosis Susceptibility at the Chromosome 9p21 Locus
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits